Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 7/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005543 | 1.00 | VDR (0.45) | VDRHDAC3HDAC6HDAC2 | |
| SCHEMBL14005438 | 1.00 | VDR (0.45) | VDRHDAC3HDAC6HDAC2 | |
| SCHEMBL4902494 | 1.00 | VDR (0.45) | VDRHDAC3HDAC6HDAC2 | |
| SCHEMBL14005437 | 0.89 | VDR (0.44) | VDR | |
| SCHEMBL4902251 | 0.89 | VDR (0.44) | VDR | |
| SCHEMBL14489200 | 0.87 | VDR (0.61) | VDR | |
| SCHEMBL14489083 | 0.87 | VDR (0.61) | VDR | |
| SCHEMBL14489112 | 0.81 | VDR (0.49) | VDR | |
| SCHEMBL4902225 | 0.81 | VDR (0.43) | VDR | |
| SCHEMBL14005412 | 0.81 | VDR (0.43) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | BIOXELL S.P.A. (IT) | 2008-11-27 | — | — | US | disclosed |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | BIOXELL S. P.A. (IT) | 2008-02-14 | — | — | US | disclosed |
| EP-1863494-A1 | USE OF VITAMIN D COMPOUNDS TO TREAT ENDOMETRIOSIS | Bioxell S.p.a. (IT) | 2007-12-12 | — | — | EP | disclosed |
| US-20070054887-A1 | Methods for treating bladder dysfunction | BIOXELL S.P.A (IT) | 2007-03-08 | — | — | US | disclosed |
| WO-2006100285-A1 | USE OF VITAMIN D COMPOUNDS TO TREAT ENDOMETRIOSIS | BIOXELL SPA (IT) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | VDR, CYP24A1, CYP27B1 | VDR 1/4885HDAC3 943/4885HDAC6 896/4885 |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | VDR, CYP24A1, CYP2R1 | VDR 1/4885HDAC3 1136/4885HDAC6 1458/4885 |
| US-20070054887-A1 | Methods for treating bladder dysfunction | CYP27B1, CYP24A1, VDR | VDR 3/4885HDAC3 2633/4885HDAC6 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.